Dr. Reddy's Laboratories Limited

NSE: DRREDDY

Pharma Pharmaceuticals

₹1,170

-0.75%EOD · 19 Aug

Dr. Reddy's Laboratories Limited is a listed Pharmaceuticals company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap

₹97,461 Cr

52W Range

₹1415 / ₹1101

Volume

1150K

53.1% delivery

1Y Return

-10.1%

P/E Ratio

30.2

P/B Ratio

2.6

ROE

8.8%

Debt / Equity

18.61

Peers in Pharma

Top 8 by market cap

Company	LTP	Market Cap	P/E	P/B	ROE %	Div Yld %
Dr. Reddy's Laboratories Limited(this stock)	₹1,170	₹97,461 Cr	30.2	2.6	8.8%	0.66%
Sun Pharmaceutical Industries LimitedSUNPHARMA	₹1,900	₹4.56 L Cr	38.3	5.5	14.7%	0.83%
Cipla LimitedCIPLA	₹1,422	₹1.15 L Cr	34.8	3.4	11.7%	0.89%
Lupin LimitedLUPIN	₹2,225	₹1.02 L Cr	18.5	4.5	26.9%	0.80%

Technical Indicators

Full analysis · objective math, not advice

Returns

-0.7%

-3.0%

+1.6%

-8.5%

-8.9%

-10.1%

Weinstein Stage

Stage 4 — Declining (downtrend)

RSI (14)

46 Neutral

Trend Template

2/7weak

RS vs Nifty (3M)

-10.4pp

Moving Averages (price vs MA)

20-DMA

₹1174

below

50-DMA

₹1235

below

150-DMA

₹1267

below

200-DMA

₹1260

below

From 52W High

-17.3%

From 52W Low

+6.3%

Support (20D)

₹1130

Resistance (20D)

₹1208

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Quality Signals

Multi-year consistency · Source: Screener annual data

ROE Consistency

0/0 years ≥15%

Revenue Growth

+6.7% CAGR

Up 8 of last 11 years

Earnings Quality

Fully cash-backed

OCF / Net Profit = 1.45x · 12/12 yrs +ve cash flow

Quality signals derived from multi-year annual financials. ROE consistency = years with ≥15% return on equity. Cash-backed = operating cash flow vs reported net profit (≥1x means earnings are converted to real cash, not just accruals). Educational reference only — not investment advice.

News & FilingsGoogle News + BSE

News via Google News · Not verified by IPOpulse · Not investment advice

Community discussion(0)

No comments yet — be the first to share your view.